Target intelligence / Profile preview

Interleukin-12 subunit alpha (IL-12A) (IL-12A)

Target
IL-12A
Molecular classification
Cytokine, Interleukin, IL-12 family
01

Overview

The p35 subunit, also known as Interleukin-12 subunit alpha (IL-12A), is a critical component of the IL-12 family of cytokines (UniProt). It heterodimerizes with EBI3 to form the immunosuppressive cytokine IL-35, and with p40 to form the pro-inflammatory cytokine IL-12 (NIH). IL-35 is primarily produced by regulatory T cells (Tregs) and regulatory B cells (Bregs), where it acts to suppress effector T cell proliferation and promote the expansion of further regulatory populations (Frontiers in Immunology). In the context of cancer, IL-35 is often upregulated in the tumor microenvironment, contributing to immune evasion by inhibiting anti-tumor cytotoxic T cell responses (PubMed). Conversely, in autoimmune and inflammatory diseases, a deficiency in IL-35 or an excess of IL-12 can lead to uncontrolled inflammation (MDPI). Therapeutic strategies targeting the p35 subunit include the use of neutralizing antibodies to block IL-35-mediated immunosuppression in oncology and the administration of recombinant IL-35 or gene therapy to restore immune tolerance in autoimmune conditions (AACR). Because p35 is shared with IL-12, drugs affecting this subunit must be carefully designed to avoid unintended effects on pro-inflammatory pathways (Nature Communications).

Other names
p35IL-12 p35Interleukin-12 subunit alphaIL12ACytotoxic lymphocyte maturation factor 35 kDa subunitCLMF p35NK cell-stimulating factor chain 1NKSF1
02

Mechanism of action

Neutralization of immunosuppressive activity in cancer or supplementation of anti-inflammatory activity in autoimmune diseases.

03

Biological functions

Immune responseImmunosuppressionT-cell proliferation inhibitionTh17 differentiation inhibitionRegulatory T-cell inductionSignal transduction
04

Disease associations

CancerInflammationAutoimmune diseaseInfectionCardiovascular disease
05

Safety considerations

Systemic immune-related adverse eventsPotential for promoting tumor growthRapid in vivo degradationImmunogenicity of recombinant proteins
06

Interacting drugs

Recombinant Interleukin-35

3 more in the full profile.

07

Biomarkers

Serum Interleukin-35 levelsInterleukin-12 subunit alpha mRNA expressionIL12A gene polymorphisms (e.g., rs2243115)

Beyond the preview

Go deeper on Interleukin-12 subunit alpha (IL-12A) (IL-12A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-12 subunit alpha (IL-12A) (IL-12A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call